Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China
Journal of Nuclear Medicine · 2024-05 · 65 (Supplement 1) · 4S-11S
DOI: 10.2967/jnumed.123.266983 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 06.05.2024. Verfasst von Liang Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. Hauptthemen laut MEDLINE: Membrane Proteins, Neoplasms, Translational Research, Biomedical. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs) have recently emerged as a focal point in global nuclear medicine, underscored by their promising applications in cancer theranostics and the diagnosis of various nononcological conditions. This review offers an in-depth summary of the existing literature on the evolution and use of FAPI tracers in China, tracing their journey from preclinical to clinical research. Moreover, this review also assesses the diagnostic accuracy of FAPI PET for the most common cancers in China, analyzes its impact on oncologic management paradigms, and investigates the potential of FAP-targeted radionuclide therapy in patients with advanced or metastatic cancer. This review also summarizes studies using FAPI PET for nononcologic disorders in China. Thus, this qualitative overview presents a snapshot of China's engagement with FAPI tracers, aiming to guide future research endeavors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
- Minnan PET Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
- Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China.
- Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China; and.
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zitieren
APA
Zhao, L., Kang, F., Pang, Y., Fang, J., Sun, L., Wu, H., Lan, X., Wang, J., & Chen, H. (2024). Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China. Journal of Nuclear Medicine, 65(Supplement 1), 4S-11S. https://doi.org/10.2967/jnumed.123.266983
Vancouver
Zhao L, Kang F, Pang Y, Fang J, Sun L, Wu H, et al. Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China. Journal of Nuclear Medicine. 2024;65(Supplement 1):4S-11S. doi:10.2967/jnumed.123.266983
BibTeX
@article{Zhao2024,
author = {Zhao, Liang and Kang, Fei and Pang, Yizhen and Fang, Jianyang and Sun, Long and Wu, Hua and Lan, XiaoLi and Wang, Jing and Chen, Haojun},
title = {Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {Supplement 1},
pages = {4S--11S},
doi = {10.2967/jnumed.123.266983}
}
EUVIMED